Literature DB >> 22478688

Biopharmaceuticals: the economic equation.

Erwin A Blackstone1, Joseph P Fuhr.   

Abstract

As more biopharmaceuticals reach the market, more attention will be given to issues such as cost-effectiveness evaluations, biosimilars, and price controls. The value biologic therapies bring to the healthcare system may take years to appreciate in full -perhaps only when policy decisions allow for their economic effects to be understood.

Year:  2007        PMID： 22478688      PMCID： PMC2651729     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  11 in total

1.  Dilemmas in regulation of the market for pharmaceuticals.

Authors:  Alan Maynard; Karen Bloor
Journal:  Health Aff (Millwood)       Date:  2003 May-Jun       Impact factor: 6.301

2.  Kaiser Permanente's evaluation and management of biotech drugs: assessing, measuring, and affecting use.

Authors:  C Douglas Monroe; Lori Potter; Mirta Millares; Anthony Barrueta; Richard Wagner
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

3.  Insurers' strategies for managing the use and cost of biopharmaceuticals.

Authors:  James C Robinson
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

4.  Biotechnology and Medicare's new technology policy: lessons from three case studies.

Authors:  Patricia Seliger Keenan; Peter J Neumann; Kathryn A Phillips
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

5.  Medicare's coverage of colorectal cancer drugs: a case study in evidence development and policy.

Authors:  Tanisha Carino; Reginald D Williams; Allison M Colbert; Perry Bridger
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

6.  Coverage options for promising technologies: Medicare's 'coverage with evidence development'.

Authors:  Sean R Tunis; Steven D Pearson
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

Review 7.  Molecular medicine, the Medicare drug benefit, and the need for cost control.

Authors:  Muriel R Gillick
Journal:  J Am Geriatr Soc       Date:  2006-09       Impact factor: 5.562

8.  Price controls: preparing for the unthinkable.

Authors:  Stephan Herrera
Journal:  Nat Biotechnol       Date:  2006-03       Impact factor: 54.908

9.  Generic biopharmaceutical drugs: an economic and policy analysis.

Authors:  Erwin A Blackstone; Joseph P Fuhr
Journal:  Biotechnol Healthc       Date:  2007-02

10.  Health care innovation: progress report and focus on biotechnology.

Authors:  J L Read; K B Lee
Journal:  Health Aff (Millwood)       Date:  1994       Impact factor: 6.301
View more
  5 in total

Review 1.  The cost-effectiveness of biopharmaceuticals: a look at the evidence.

Authors:  Andrew W Wilson; Peter J Neumann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Projecting expenditure on medicines in the UK NHS.

Authors:  Phill O'Neill; Jorge Mestre-Ferrandiz; Ruth Puig-Peiro; Jon Sussex
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

Review 3.  Update on biosimilars in rheumatology.

Authors:  Adam Rischin; Andrew J K Östör
Journal:  Inflammopharmacology       Date:  2017-03-07       Impact factor: 4.473

4.  Biosimilars: How Can Payers Get Long-Term Savings?

Authors:  Jorge Mestre-Ferrandiz; Adrian Towse; Mikel Berdud
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

5.  Low-Cost, Large-Scale Production of the Anti-viral Lectin Griffithsin.

Authors:  John S Decker; Romel Menacho-Melgar; Michael D Lynch
Journal:  Front Bioeng Biotechnol       Date:  2020-08-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.